Prometheus Biosciences Inc, a biopharmaceutical company involved in the discovery, development, and commercialisation of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases, announced yesterday that it has named Thierry Dervieux, PharmD, PhD, DABCC as its new chief development officer, diagnostics, and medical laboratory director.
Dr Dervieux joins Prometheus Biosciences from Exagen Diagnostics where he served as chief scientific officer and medical director. Prior to joining Exagen, Dr Dervieux was vice president of research and development at Cypress Bioscience Inc and senior director of research and development with Proprius Pharmaceuticals Inc. Prior to that, he served as principal scientist and director of research and development at Prometheus Laboratories.
Mark McKenna, chief executive officer of Prometheus Biosciences, said, 'Thierry's deep expertise in the development of innovative diagnostic assays and drug monitoring tools will benefit us greatly as we continue to advance our novel precision medicine platform for GI and autoimmune conditions. We are thrilled to welcome Thierry and we look forward to his contributions as we take Prometheus to the next level.'
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial